STAT3 and colorectal carcinoma: Regardless, our data advocate exercising caution when considering IL-22 as a therapeutic target for treatment of established CRC and suggest that patients need to be stratified based on expression of the IL-22 receptor, STAT3 repressors, and possibly other mutations acquired by cancerous cells.